Skip to main content
Clinical Trials/NL-OMON37942
NL-OMON37942
Completed
Not Applicable

Arrhythmia Risk Stratification in a Clinical Patient Cohort and Correlation with Genotype and Environmental Modulators - EU-Trig Treat Study

Academisch Medisch Centrum0 sites100 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
arrhythmia risk stratification
Sponsor
Academisch Medisch Centrum
Enrollment
100
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Clinical indication (primary and secondary prevention of SCD) for ICD implantation/ICD exchange or chronically implanted ICD
  • \- Age \> 18 years
  • \- Written informed consent
  • \- Negative pregnancy test in women of childbearing potential
  • \- No participation in other clinical trials within one month before and after enrolment into the study;\- Cardiac resynchronisation therapy (CRT) devices are excluded from the study (for their special effects in reversal of repolarisation remodeling) for at least 6 months after implantation, thereafter single\- and dual\-chamber devices are still to be preferred. Single and dual\-chamber device exhange patients recruited to the invasive studies must not have RV pacing \> 20% of the time.
  • \- Up to 60% of all patients with coronary artery disease, with or without a history of myocardial infarction (occurrence of STEMI, NSTEMI and highest CKmax will be recorded). This will be monitored by Dr. Eva Müller from the clinical IFS institute in G\*ttingen.
  • \- Up to 350 patients with non\-ischemic cardiomyopathies (180 dilated cardiomyopathy \[DCM], 70 hypertrophic cardiomyopathy \[HCM] / hypertrophic obstructive cardiomyopathy \[HOCM], 20 arrhythmogenic right ventricular cardiomyopathy \[ARVC], channelopathies (30 Brugada syndrome, 20 long QT syndrome, 10 catecholaminergic polymorphic ventricular tachycardia \[CPVT]) or idiopathic VT/VF (n\=20\) with any LV ejection fraction. This will be monitored by Dr. Eva Müller from the clinical IFS institute in G\*ttingen.

Exclusion Criteria

  • \- Unstable cardiac disease such as decompensated heart failure (NYHA class IV) or acute coronary syndrome or symptomatic arrhythmias
  • \- Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery less than 3 months ago
  • \- ICDs unable to deliver programmed ventricular stimulation via programmer (in the chronic ICD group)
  • \- Permanent atrial fibrillation if more than 20% of all patients at a given time during the study are enrolled, this condition will be flagged by the study manager Dr. Eva Müller from the clinical IFS institute in G\*ttingen which also runs the secure clinical database.

Outcomes

Primary Outcomes

Not specified

Similar Trials